retatrutide liver STUDY: Novel “Triagonist” Resolved Steatosis in Over 85% of Patients with MASLD and Obesity Retatrutide vs Tirzepatide (2026): Differences

Berberine has secondary evidence for metabolic support

But is the Impossible Burger a healthy alternative to beef

Step 5: Swirl gently

In Eli Lillys Phase 3 TRIUMPH-4 trial (December 2025), participants at the 12mg dose lost an average of 28.7% of body weight at 68 weeks up to 71.2 lbs per person

This was a landmark moment because it represented global recognition of GLP-1 medications as a legitimate long-term treatment for obesity rather than a temporary or supplementary intervention

But the magnitude of this particular development is like nothing seen since the development of antibiotics for one simple reason every organ in the body is affected by the disease of obesity and by treating obesity you treat every organ